Comparative Pharmacology
Head-to-head clinical analysis: DALVANCE versus SUSTIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALVANCE versus SUSTIVA.
DALVANCE vs SUSTIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing transglycosylation and transpeptidation.
Non-nucleoside reverse transcriptase inhibitor (NNRTI) which binds to reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities, causing a conformational change and inhibiting HIV-1 replication.
15-20 mg/kg intravenously once daily for 7-14 days
600 mg orally once daily, preferably at bedtime to minimize central nervous system symptoms; take on an empty stomach (1 hour before or 2 hours after a meal).
None Documented
None Documented
Terminal elimination half-life is approximately 257 hours (about 10.7 days), supporting a once-weekly dosing regimen (week 1 loading dose). Prolonged half-life allows sustained exposure.
42 hours (range 22–72), steady state achieved in ~7–10 days.
Primarily eliminated as unchanged drug via renal excretion (approximately 80% of administered dose). A minor amount (5%) is excreted in feces as unchanged drug. The remainder is metabolized, but no active metabolites are formed.
Fecal (primarily, ~51% as metabolites, ~14% as unchanged drug); renal (~34%, <1% unchanged).
Category C
Category C
Non-Nucleoside Reverse Transcriptase Inhibitor
Non-Nucleoside Reverse Transcriptase Inhibitor